COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Aflac ST1001 Prolonged Isotretinoin (Aflac ST1001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01319838
Recruitment Status : Withdrawn (no patient enrollment)
First Posted : March 22, 2011
Last Update Posted : December 10, 2013
Children's Healthcare of Atlanta
Information provided by (Responsible Party):
Muna Qayed, Emory University

Brief Summary:

Neuroblastoma is a cancer of the nervous system and accounts for 15% of cancer related deaths in children. With the advancement of treatment therapies, the long term survival rate has progressed to approximately 50%. The therapy used for treatment, however, is very toxic and associated with serious long-term side effects. Treatment for neuroblastoma typically includes chemotherapy, surgery, stem cell transplantation, radiation therapy, and immunotherapy. At the end of this treatment, children with neuroblastoma commonly take the drug isotretinoin for 6 months. Isotretinoin maintains the response to previous treatments and helps turn the remaining cancer cells into normal nerve cells.

Most patients often respond to this treatment at first but are at a high-risk for the cancer coming back. The majority of the children who relapse after treatment or develop recurrent disease do so in the first two years following the completion of therapy and there are no current treatments to cure those who relapse. This study will explore whether or not extending the therapy with isotretinoin from 6 months to 24 months will help prevent the cancer from coming back without causing severe side effects.

Condition or disease Intervention/treatment Phase
Neuroblastoma Drug: Isotretinoin Phase 1

Detailed Description:

Neuroblastoma is the most common extracranial solid tumor of childhood and accounts for 15% of all pediatric cancer related deaths. The majority of patients present with high-risk disease that is widely metastatic and aggressive. Historically, less than 30% of these patients achieved long-term disease-free survival and the majority of relapses occurred within the first 24 months following treatment. Survival rates have modestly improved with the addition of high-dose chemotherapy and stem cell rescue, radiotherapy, surgery and biologic therapy, yet 50% of patients still succumb to their disease. Current treatment of neuroblastoma also carries significant acute toxicities and those patients that are cured suffer significant long-term treatment-related morbidities. Therefore, children with high-risk neuroblastoma are in need of novel therapeutic strategies that will improve cure rates without adding to acute and long-term toxicities.

Retinoids, derivatives of vitamin A, have been repeatedly shown to arrest cell growth of neuroblastoma cells in vitro by causing differentiation. Clinical trials in relapsed neuroblastoma patients with bulky tumors failed to show significant responses to retinoid therapy. Subsequently, however, a sentinel randomized clinical trial demonstrated that isotretinoin(13-cis-retinoic acid), when given to patients with minimal residual disease following consolidation chemotherapy, independently improved the overall survival of patients with high-risk neuroblastoma. The treatment regimen included isotretinoin for 2 weeks followed by a 2 week rest period for 6 treatment cycles. The treatment was very well tolerated with minimal side effects. The duration of treatment, 6 months, was arbitrarily chosen and currently many institutions implement prolonged retinoic acid treatment in patients with relapsed high-risk disease, yet no formal study has been done to statistically show improved survival with prolonged biotherapy.

To improve the progression-free survival in patients with high-risk neuroblastoma this trial will prolong therapy with isotretinoin to 24 months, the time window in which most relapses occur. The treatment is anticipated to be well tolerated with no increase in adverse side effects based on the benign side effect profile of patients who have received the typical 6 month treatment course. The trial will consist of a single arm of 20 high-risk neuroblastoma patients who will receive a total of 24 cycles of isotretinoin (2 weeks on treatment followed by 2 weeks of rest) compared to the historical and current COG study treatment of 6 cycles. Patients will be accrued over a 3-year period.

The toxicity and tolerability of a prolonged course of isotretinoin biologic therapy will be closely monitored with a focus on neuropsychologic and bone toxicities, and isotretinoin drug levels will be measured to determine if there is a correlation between levels and anti-tumor efficacy or toxicities. This will provide complementary data to support future national cooperative group trials.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prolonged Isotretinoin Therapy in Patients With High Risk Neuroblastoma
Study Start Date : March 2011
Actual Primary Completion Date : December 2013
Actual Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Neuroblastoma

Arm Intervention/treatment
Experimental: isotretinoin prolongation
Prolonged treatment with isotretinoin, extending standard 6 month duration to 2 years
Drug: Isotretinoin
>12 kg: 160 mg/m2/day, given PO, divided BID <=12 kg: 5.33 mg/kg/day, given PO, dividied BID doses given days 1-14 of 28 day cycle for 24 consecutive cycles

Primary Outcome Measures :
  1. Progression free survival [ Time Frame: 5 years after treatment completed ]
    To determine the progression free survival in patients with high risk neuroblastoma who receive a prolonged course of biologic therapy with isotretinoin

  2. Isotretinoin toxicity [ Time Frame: 5 years after treatment completed ]
    To determine the toxicity and tolerability of a prolonged course of isotretinoin biologic therapy

Secondary Outcome Measures :
  1. Bone growth effect [ Time Frame: 5 years after treatment completed ]
    To observe any effects on bone growth and metabolism in patients receiving a prolonged course of isotretinoin biologic therapy

  2. Isotretinoin pharmacokinetic profile [ Time Frame: 1 year after treatment completed ]
    To determine changes in time of the pharmacokinetic profile of a prolonged course of isotretinoin biologic immunotherapy

  3. Neurologic or psychologic sequelae [ Time Frame: 1 year after treatment completed ]
    To observe the incidence of neurologic or psychologic sequelae resulting from a prolonged course of isotretinoin biologic therapy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 30 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • <=30 years of age
  • histologic verification of neuroblastoma
  • no active measurable disease on CT/MRI
  • ultra high risk status by having mixed response, no response or stable disease following initial treatment or by having recurrent neuroblastoma
  • Karnofsky >=50% for patients >16 years and Lansky >=50% for patients <=16 years
  • patients must have completed high risk therapy
  • organ function as defined in protocol

Exclusion Criteria:

  • patients with active measurable disease
  • patients who are pregnant or breast-feeding
  • concomitant medications stopped as indicated in protocol
  • patients with uncontrolled infection
  • patients with history of depression or psychotic disorder requiring medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01319838

Layout table for location information
United States, Georgia
Children's Healthcare of Atlanta
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Emory University
Children's Healthcare of Atlanta
Layout table for investigator information
Principal Investigator: Howard Katzenstein, MD Children's Healthcare of Atlanta/Emory University
Additional Information:
Layout table for additonal information
Responsible Party: Muna Qayed, Principal Investigator, Emory University Identifier: NCT01319838    
Other Study ID Numbers: IRB00047148
Aflac ST1001 ( Other Identifier: Other )
First Posted: March 22, 2011    Key Record Dates
Last Update Posted: December 10, 2013
Last Verified: December 2013
Keywords provided by Muna Qayed, Emory University:
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Dermatologic Agents